{"id":"https://openalex.org/W2986674840","doi":"https://doi.org/10.1182/blood-2019-122846","title":"Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma","display_name":"Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma","publication_year":2019,"publication_date":"2019-11-13","ids":{"openalex":"https://openalex.org/W2986674840","doi":"https://doi.org/10.1182/blood-2019-122846","mag":"2986674840"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2019-122846","doi":"https://doi.org/10.1182/blood-2019-122846","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2019-122846","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5085820043","display_name":"Timothy J. Voorhees","orcid":"https://orcid.org/0000-0001-7603-6454","observed_orcids":["https://orcid.org/0000-0001-7603-6454"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Timothy J Voorhees","raw_affiliation_strings":["Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075085884","display_name":"Natalie Sophia Grover","orcid":"https://orcid.org/0000-0002-1346-3157","observed_orcids":["https://orcid.org/0000-0002-1346-3157"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Natalie S Grover","raw_affiliation_strings":["Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086211539","display_name":"Anne Beaven","orcid":"https://orcid.org/0000-0002-9174-3568","observed_orcids":["https://orcid.org/0000-0002-9174-3568"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anne Beaven","raw_affiliation_strings":["Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070252326","display_name":"Steven I. Park","orcid":"https://orcid.org/0000-0001-5674-6408","observed_orcids":["https://orcid.org/0000-0001-5674-6408"]},"institutions":[{"id":"https://openalex.org/I4210100342","display_name":"Levine Cancer Institute","ror":"https://ror.org/0174nh398","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334069289","https://openalex.org/I4210100342"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven I Park","raw_affiliation_strings":["Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC","institution_ids":["https://openalex.org/I4210100342"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091401985","display_name":"J. Kaitlin Morrison","orcid":"https://orcid.org/0009-0007-1298-3728","observed_orcids":["https://orcid.org/0009-0007-1298-3728"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Kaitlin Morrison","raw_affiliation_strings":["Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102818653","display_name":"Catherine Joyce Arago Cheng","orcid":"https://orcid.org/0000-0002-1619-9320","observed_orcids":["https://orcid.org/0000-0002-1619-9320"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Catherine Joyce Arago Cheng","raw_affiliation_strings":["Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036821051","display_name":"Spencer Laing","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Spencer Laing","raw_affiliation_strings":["Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023649972","display_name":"Gianpietro Dotti","orcid":"https://orcid.org/0000-0002-2639-8526","observed_orcids":["https://orcid.org/0000-0002-2639-8526"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gianpietro Dotti","raw_affiliation_strings":["Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065544223","display_name":"Barbara Savoldo","orcid":"https://orcid.org/0000-0002-7571-3887","observed_orcids":["https://orcid.org/0000-0002-7571-3887"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Barbara Savoldo","raw_affiliation_strings":["Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5026510629","display_name":"Jonathan Stuart Serody","orcid":"https://orcid.org/0000-0003-4568-1092","observed_orcids":["https://orcid.org/0000-0003-4568-1092"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan S Serody","raw_affiliation_strings":["Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"134","issue":"Supplement_1","first_page":"3233","last_page":"3233"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9345999956130981,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9345999956130981,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.04919999837875366,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.00559999980032444,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.8989999890327454},{"id":"https://openalex.org/keywords/relapsed-refractory-hodgkin-lymphoma","display_name":"relapsed/refractory Hodgkin lymphoma","score":0.9419999718666077}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7758157253265381},{"id":"https://openalex.org/C70905583","wikidata":"https://www.wikidata.org/wiki/Q3648608","display_name":"CD30","level":3,"score":0.7414076924324036},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5230451822280884},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.5187795162200928},{"id":"https://openalex.org/C2778191690","wikidata":"https://www.wikidata.org/wiki/Q422324","display_name":"Brentuximab vedotin","level":4,"score":0.5047250986099243},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.4988582134246826},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.426676869392395},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4259440302848816},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.36850911378860474},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3628697693347931}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2019-122846","doi":"https://doi.org/10.1182/blood-2019-122846","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2019-122846","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4310127384","https://openalex.org/W3044350523","https://openalex.org/W2513177163","https://openalex.org/W4406319028","https://openalex.org/W4405047656","https://openalex.org/W4220882036","https://openalex.org/W2196039424","https://openalex.org/W2910288910","https://openalex.org/W2913908221","https://openalex.org/W2913053020"],"abstract_inverted_index":{"Background:":[0],"The":[1,190,287],"safety":[2,52],"and":[3,53,87,113,177,274,314,351,515,532],"efficacy":[4,54,472],"of":[5,34,46,55,70,92,107,141,154,170,172,206,227,239,325,331,385,396,401,413,418,434,452,473,507,509,530,562,585],"treating":[6],"pts":[7,71,94,143,208,220,269,283,305,310,345,421,453,480,490],"with":[8,13,72,95,160,166,212,224,338,355,370,411,429,454,487,495],"relapsed/refractory":[9],"(r/r)":[10],"CD30+":[11],"lymphomas":[12],"chimeric":[14],"receptor":[15],"modified":[16],"T":[17,503],"cells":[18,38],"targeting":[19],"the":[20,44,51,89,105,138,142,155,249,303,323,328,371,541],"CD30":[21],"molecule":[22],"(CD30.CAR-T)":[23],"has":[24,39],"been":[25,40,158,210],"recently":[26],"demonstrated":[27],"(Grover":[28],"et":[29],"al.,":[30],"ASH":[31],"2018).":[32],"Expression":[33],"PD-1":[35],"on":[36,558],"CD30.CAR-T":[37,61,82,101,164,196,240,253,291,356,441,461,476,533],"observed":[41],"post-infusion":[42],"at":[43,104,110,425],"time":[45,192,289,324],"disease":[47,244,272,279,348,500],"recurrence.":[48],"To":[49,445],"determine":[50],"anti-PD-1":[56],"mAb":[57],"therapy":[58,103,197,380,397,414],"(CPI)":[59],"post":[60],"cell":[62,102,136,357,442,462,504],"therapy,":[63,137,165,358],"we":[64],"present":[65],"a":[66,167,182,225,236,259,266,312,318,360,430,513],"retrospective":[67],"cohort":[68,146,469],"review":[69],"r/r":[73,96,455,544],"Hodgkin":[74],"lymphoma":[75],"(HL)":[76],"who":[77,98,457,481],"subsequently":[78,114,284],"received":[79,115,235,458],"CPI":[80,116,161,194,213,293,350,366,459,474,496,525,531],"after":[81,100,217,241,382,398,415,460,475,484,501],"progression.":[83],"Methods:":[84],"We":[85],"followed":[86],"analyzed":[88],"clinical":[90,215,471],"outcome":[91],"5":[93,207,282,304],"HL":[97,456],"progressed":[99,483],"University":[106],"North":[108],"Carolina":[109],"Chapel":[111],"Hill":[112],"to":[117,134,163,195,231,292,379,524,527],"treat":[118],"relapsed":[119,499],"disease.":[120],"Clinical":[121],"responses":[122],"in":[123,144,341,363,394,478,540],"follow":[124,427],"up":[125,428],"were":[126,221,352,422],"determined":[127],"per":[128],"local":[129],"radiologist":[130],"assessment.":[131],"Results:":[132],"Prior":[133],"CAR-T":[135],"average":[139],"age":[140],"this":[145,448,468],"was":[147,198,294,333,368],"36":[148],"years":[149,436],"old":[150],"(range,":[151,175,201,297,437],"26-54).":[152],"Four":[153,506],"five":[156,508],"had":[157,258,265,270,277,482],"treated":[159,211,354],"prior":[162,230,526],"median":[168,191,226,288,329,431],"duration":[169,330],"response":[171,180,184,261,332,340,494,521],"224":[173],"days":[174,200,296,335],"81-280)":[176],"best":[178],"objective":[179,493],"being":[181],"partial":[183],"(PR)":[185],"for":[186,307,498,543],"all":[187],"4":[188,309],"pts.":[189,343],"from":[193,290,439],"483":[199],"25-1174":[202],"days).":[203],"A":[204,403],"total":[205],"have":[209],"following":[214,248,349],"progression":[216],"CD30.CAR-T.":[218,232,528],"All":[219,281,420,489],"heavily":[222],"pre-treated":[223],"8":[228,383,416],"therapies":[229],"One":[233,374],"pt":[234,256,264,276,316,375,388,405],"second":[237],"infusion":[238],"having":[242],"stable":[243,271],"(SD)":[245],"6":[246],"weeks":[247],"first":[250,450],"infusion.":[251],"Following":[252],"infusion,":[254],"1":[255,263,275,315],"initially":[257],"complete":[260],"(CR),":[262],"PR,":[267],"2":[268],"(SD),":[273],"progressive":[278],"(PD).":[280],"developed":[285,346,376,389,406],"PD.":[286],"132":[295],"67-393":[298],"days),":[299],"(Table":[300],"1).":[301,321],"Of":[302],"evaluable":[306],"response,":[308],"achieved":[311,317,491,512,518],"CR":[313,362,514],"PR":[319],"(Figure":[320],"At":[322],"data":[326],"cutoff,":[327],"212":[334],"(range":[336],"139-836)":[337],"ongoing":[339],"3":[342,391,516],"Two":[344],"recurrent":[347],"again":[353],"achieving":[359],"2nd":[361],"both":[364],"cases.":[365],"use":[367],"associated":[369],"expected":[372],"toxicities.":[373],"neuropathy,":[377],"leading":[378],"discontinuation":[381,395,412],"months":[384,400,417],"therapy.":[386,402,419,443,463,505],"Another":[387],"grade":[390],"colitis,":[392],"resulting":[393],"25":[399],"third":[404],"pneumonitis":[407],"(prior":[408],"mediastinal":[409],"radiation),":[410],"still":[423],"alive":[424],"last":[426],"overall":[432],"survival":[433],"2.44":[435],"0.93-2.76)":[438],"initial":[440],"Conclusion:":[444],"our":[446],"knowledge,":[447],"is":[449],"report":[451],"Though":[464],"limited":[465],"by":[466],"size,":[467],"demonstrates":[470],"even":[477],"those":[479],"previous":[485],"treatment":[486],"CPI.":[488],"an":[492,519,536,559],"administered":[497],"CD30.CAR":[502],"these":[510],"patients":[511,517],"improved":[520],"when":[522],"compared":[523],"Combination":[529],"may":[534],"be":[535],"attractive":[537],"study":[538],"design":[539],"future":[542],"HL.":[545],"Disclosures":[546],"Grover:":[547],"Seattle":[548,577],"Genetics:":[549,578],"Consultancy.":[550],"Park:BMS:":[551],"Consultancy,":[552,571],"Research":[553,572,579,599,603,606,609],"Funding;":[554,573,607],"Rafael":[555],"Pharma:":[556],"Membership":[557],"entity's":[560],"Board":[561],"Directors":[563],"or":[564],"advisory":[565],"committees;":[566],"G1":[567],"Therapeutics:":[568],"Consultancy;":[569],"Teva:":[570],"Gilead:":[574],"Speakers":[575,581],"Bureau;":[576],"Funding,":[580],"Bureau.":[582],"Savoldo:Baylor":[583],"College":[584],"Medicine:":[586],"Patents":[587],"&":[588],"Royalties:":[589],"CAR.CD30":[590],"patent;":[591],"Bluebirdbio:":[592],"Other:":[593,598,602],"research":[594],"agreement;":[595],"Cell":[596],"Medica:":[597],"Agreement;":[600],"Bellicum:":[601],"Agreement.":[604],"Serody:Merck:":[605],"GlaxoSmithKline:":[608],"Funding.":[610]},"counts_by_year":[{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2019-11-22T00:00:00"}